Prevalence of Pathogenic Mutations in Cancer Predisposition Genes among Pancreatic Cancer Patients

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Cancer Epidemiology, Biomarkers and Prevention

• Publication date

  2015-10-19

• Fields of study

  Medicine

• Identifiers
  DOI 10.1158/1055-9965.EPI-15-0455PMID 26483394PMCID PMC4754121
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Prevalence of germline mutations in cancer predisposition genes in patients with pancreatic cancer.

  2015influential reference
• Cancer statistics, 2014

  2014cited by this paper
• Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States.

  2014cited by this paper
• Exome sequencing identifies FANCM as a susceptibility gene for triple-negative breast cancer

  2014cited by this paper
• PatternCNV: a versatile tool for detecting copy number changes from exome sequencing data

  2014cited by this paper
• BRCA1, BRCA2, PALB2, and CDKN2A Mutations in Familial Pancreatic Cancer (FPC): A PACGENE Study

  2014cited by this paper
• Diagnosis and management of pancreatic cancer

  2013cited by this paper
• Risks of primary extracolonic cancers following colorectal cancer in lynch syndrome.

  2012cited by this paper
• ATM mutations in patients with hereditary pancreatic cancer.

  2012cited by this paper
• Identifying people at a high risk of developing pancreatic cancer

  2012cited by this paper
• Prevalence of CDKN2A mutations in pancreatic cancer patients: implications for genetic counseling

  2011cited by this paper
• Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutations

  2011cited by this paper
• Integrative Genomics Viewer

  2011cited by this paper
• Risk of Pancreatic Cancer in Families With Lynch Syndrome

  2011cited by this paper
• TP53 germline mutation testing in 180 families suspected of Li–Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes

  2010cited by this paper
• Risk of pancreatic cancer in families with Lynch syndrome.

  2009cited by this paper
• The Prevalence of BRCA2 Mutations in Familial Pancreatic Cancer

  2007cited by this paper
• Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada.

  2006cited by this paper
• Low Frequency of CHEK2 Mutations in Familial Pancreatic Cancer

  2006influential reference
• Increased prevalence of the BRCA2 polymorphic stop codon K3326X among individuals with familial pancreatic cancer

  2005cited by this paper
• Lynch Syndrome (HNPCC) and Microsatellite Instability

  2004cited by this paper
• Very high risk of cancer in familial Peutz-Jeghers syndrome.

  2000cited by this paper
• Cancer Risks in BRCA 2 Mutation Carriers The Breast Cancer Linkage Consortium

  1999cited by this paper
• Cancer risks in BRCA2 mutation carriers.

  1999cited by this paper
• Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations.

  1995cited by this paper
• Pancreatitis and the risk of pancreatic cancer

  1993cited by this paper
• Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study Group.

  1993cited by this paper
• Cancer statistics

  1989cited by this paper
• Malignant neoplasms in the families of patients with ataxia-telangiectasia.

  1976cited by this paper

• A serum-derived 3D tumor model platform for personalized prediction and monitoring of chemotherapeutic response in pancreatic ductal adenocarcinoma

  2026cites this paper
• MicroRNA-Based Triage of HPV-Positive Women Using Liquid-Based Cytology: Diagnostic Performance and Network-Level Insights.

  2026cites this paper
• Genomic instability, DNA damage response and telomere homeostasis in pancreatic cancer.

  2025cites this paper
• Factors associated with actionable gene aberrations in pancreatic cancer based on the C-CAT database

  2025cites this paper
• BARD1: A Friend or Foe in Pancreatic Ductal Adenocarcinoma?

  2025cites this paper
• In silico study of novel coumarin derivatives as potential agents in the pancreatic cancer treatment.

  2024cites this paper
• Bridging the Divide: From Universal Germline Testing Guidance to Real-World Implementation in Pancreatic Cancer Care.

  2024cites this paper
• Integration of Germline Genetic Testing Into Routine Clinical Practice for Patients With Pancreatic Adenocarcinoma

  2024cites this paper
• Prevalence of germline variants in Brazilian pancreatic carcinoma patients

  2024cites this paper
• Hereditary Cancer Genes and Related Risks.

  2023cites this paper
• Proposing new early detection indicators for pancreatic cancer: Combining machine learning and neural networks for serum miRNA-based diagnostic model

  2023cites this paper
• Genetic assessment of pathogenic germline alterations in lysosomal genes among Asian patients with pancreatic ductal adenocarcinoma

  2023cites this paper
• Cost-Effectiveness Analysis of Screening for Pancreatic Cancer Among High-Risk Populations

  2023cites this paper
• Clinicians’ and Patients’ Perceptions and Use of the Word “Cured” in Cancer Care: An Italian Survey

  2023cites this paper
• Evaluation of inherited germline mutations in cancer susceptibility genes among pancreatic cancer patients: a single-center study

  2023cites this paper
• BARD1 germline variants induce haploinsufficiency and DNA repair defects in neuroblastoma

  2023cites this paper
• Prevalence and Risk Factors of Germline Pathogenic Variants in Pancreatic Ductal Adenocarcinoma

  2023cites this paper
• Management of individuals with germline pathogenic/likely pathogenic variants in CHEK2: A clinical practice resource of the American College of Medical Genetics and Genomics (ACMG).

  2023cites this paper
• Pancreatic Ductal Carcinoma Risk Associated With Hereditary Cancer-Risk Genes

  2022cites this paper
• KRAS mutation allele frequency threshold alters prognosis in right‐sided resected pancreatic cancer

  2022cites this paper
• Poly Adenosine Diphosphate-Ribose Polymerase (PARP) Inhibitors in Pancreatic Cancer

  2022cites this paper
• Epidemiology and geographic distribution of BRCA1-2 and DNA Damage response genes pathogenic variants in pancreatic ductal adenocarcinoma patients.

  2022cites this paper
• Familial Predisposition and Genetic Risk Factors Associated with Pancreatic Cancer.

  2022cites this paper
• A Cautionary Tale of Sexing by Methylation: Hybrid Bisulfite-Conversion Sequencing of Immunoprecipitated Methylated DNA in Chrysemys picta Turtles with Temperature-Dependent Sex Determination Reveals Contrasting Patterns of Somatic and Gonadal Methylation, but No Unobtrusive Sex Diagnostic

  2022cites this paper
• Novel ATM Gene c.5644 C > T (p.Arg1882*) Variant Detected in a Patient with Pancreatic Adenocarcinoma and Two Primary Non-Small Cell Lung Adenocarcinomas: A Case Report

  2022cites this paper
• Germline Testing for Individuals with Pancreatic Adenocarcinoma and Novel Genetic Risk Factors.

  2022cites this paper
• The Evolving Paradigm of Germline Testing in Pancreatic Ductal Adenocarcinoma and Implications for Clinical Practice.

  2022cites this paper
• Impact of comprehensive family history and genetic analysis in the multidisciplinary pancreatic tumor clinic setting

  2022cites this paper
• Genetic testing to guide screening for pancreatic ductal adenocarcinoma: Results of a microsimulation model.

  2022cites this paper
• HuR Plays a Role in Double-Strand Break Repair in Pancreatic Cancer Cells and Regulates Functional BRCA1-Associated-Ring-Domain-1(BARD1) Isoforms

  2022cites this paper
• Impact of Endoscopic Ultrasound-Guided Tissue Acquisition on Decision-Making in Precision Medicine for Pancreatic Cancer: Beyond Diagnosis

  2021cites this paper
• Clinical Significance of Germline Cancer Predisposing Variants in Unselected Patients with Pancreatic Adenocarcinoma

  2021cites this paper
• Targeted Therapies for Pancreatic Cancer: Overview of Current Treatments and New Opportunities for Personalized Oncology

  2021cites this paper
• Cancer surveillance awareness and practice among families at increased risk for pancreatic adenocarcinoma

  2021cites this paper
• PALLD mutation in a European family conveys a stromal predisposition for familial pancreatic cancer

  2021cites this paper
• Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.

  2021influential citation
• Tumor Signature Analysis Implicates Hereditary Cancer Genes in Endometrial Cancer Development

  2021cites this paper
• Impact of changing guidelines on genetic testing and surveillance recommendations in a contemporary cohort of breast cancer survivors with family history of pancreatic cancer

  2021cites this paper
• Clinical implications of the molecular characterization of intraductal papillary mucinous neoplasms of the pancreas

  2021cites this paper
• Is cancer a matter of luck?

  2021cites this paper
• Establishment and verification of a prognostic model of liver cancer by RNA-binding proteins based on the TCGA database

  2021cites this paper
• Familial Pancreatic Cancer

  2021cites this paper
• Recommendations for a More Organized and Effective Approach to the Early Detection of Pancreatic Cancer from the PRECEDE (Pancreatic Cancer Early Detection) Consortium.

  2021cites this paper
• Clinical Impact of Pathogenic Germline Variants in Pancreatic Cancer: Results From a Multicenter, Prospective, Universal Genetic Testing Study

  2021cites this paper
• The fellowship of the RING: BRCA1, its partner BARD1 and their liaison in DNA repair and cancer.

  2021cites this paper
• Islet Inflammation: The Link between Type 2 Diabetes and Pancreatic Cancer

  2021cites this paper
• Significant detection of new germline pathogenic variants in Australian Pancreatic Cancer Screening Program participants

  2021cites this paper
• Hereditary Syndromes and Pancreatic Cancer

  2021cites this paper
• A systematic review of the prevalence of germline pathogenic variants in patients with pancreatic cancer

  2021cites this paper
• The genetics of ductal adenocarcinoma of the pancreas in the year 2020: dramatic progress, but far to go

  2020cites this paper
• BRCA Mutations in Pancreas Cancer: Spectrum, Current Management, Challenges and Future Prospects

  2020cites this paper
• Cost-effectiveness analysis of universal germline testing for patients with pancreatic cancer.

  2020cites this paper
• NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020.

  2020cites this paper
• Germline genetic variability in pancreatic cancer risk and prognosis.

  2020cites this paper
• Retrospective review of outcomes in patients with DNA-damage repair related pancreatic cancer

  2020cites this paper
• Detection of germline variants using expanded multigene panels in patients with localized pancreatic cancer.

  2020cites this paper
• Precision Oncology in Pancreatic Cancer. From Surgery- to Genetic-Based Chemotherapy.

  2020cites this paper
• Literature Review of BARD1 as a Cancer Predisposing Gene with a Focus on Breast and Ovarian Cancers

  2020cites this paper
• The Effects of Genetic and Epigenetic Alterations of BARD1 on the Development of Non-Breast and Non-Gynecological Cancers

  2020cites this paper
• ATM Serine/Threonine Kinase and its Role in Pancreatic Risk

  2020cites this paper
• An Emerging Paradigm for Germline Testing in Pancreatic Ductal Adenocarcinoma and Immediate Implications for Clinical Practice: A Review.

  2020cites this paper
• Precision Prevention: The Current State and Future of Genomically Guided Cancer Prevention.

  2020cites this paper
• CMAR_A_211151 2731..2742

  2020cites this paper
• CHEK2 Germline Variants in Cancer Predisposition: Stalemate Rather than Checkmate

  2020cites this paper
• Using Co-segregation and Loss of Heterozygosity Analysis to Define the Pathogenicity of Unclassified Variants in Hereditary Breast Cancer Patients

  2020cites this paper
• DNA damage repair as a target in pancreatic cancer: state-of-the-art and future perspectives

  2020cites this paper
• Beyond BRCA: Review of Hereditary Syndromes Predisposing to Breast Cancer.

  2019cites this paper
• Translational genomics in pancreatic ductal adenocarcinoma: A review with re-analysis of TCGA dataset.

  2019cites this paper
• Evaluating Susceptibility to Pancreatic Cancer: ASCO Provisional Clinical Opinion.

  2019cites this paper
• Genetic analysis of subsequent second primary malignant neoplasms in long-term pancreatic cancer survivors suggests new potential hereditary genetic alterations

  2019cites this paper
• Genetics of Familial and Sporadic Pancreatic Cancer.

  2019cites this paper
• Type-3c Diabetes Mellitus, Diabetes of Exocrine Pancreas - An Update.

  2019cites this paper
• Genomic Features and Clinical Management of Patients with Hereditary Pancreatic Cancer Syndromes and Familial Pancreatic Cancer

  2019influential citation
• Prevalence of Germline Mutations Associated With Cancer Risk in Patients With Intraductal Papillary Mucinous Neoplasms.

  2019cites this paper
• Family communication and patient distress after germline genetic testing in individuals with pancreatic ductal adenocarcinoma

  2019cites this paper
• Analysis of Heritability and Genetic Architecture of Pancreatic Cancer: A PanC4 Study

  2019cites this paper
• Prevalence and characteristics of likely-somatic variants in cancer susceptibility genes among individuals who had hereditary pan-cancer panel testing.

  2019cites this paper
• The Role of BRCA Testing in Hereditary Pancreatic and Prostate Cancer Families.

  2019cites this paper
• Genetic testing for hereditary breast and ovarian cancer and the USPSTF recommendations

  2019cites this paper
• Genetic Counseling for Pancreatic Cancer

  2019cites this paper
• Precision Cancer Medicine: Challenges and Opportunities

  2019cites this paper
• Update on PARP inhibitor therapy for solid tumors

  2019cites this paper
• Pancreatic Cancer Surveillance: Who, When, and How

  2019cites this paper
• Risk Assessment and Genetic Testing for Inherited Gastrointestinal Syndromes.

  2019cites this paper
• Insulin Resistance Is a Common Core Tethered to Diabetes and Pancreatic Cancer Risk

  2019cites this paper
• Managing Germline Findings from Molecular Testing in Precision Oncology

  2019cites this paper
• Prospective study of germline genetic testing in incident cases of pancreatic adenocarcinoma

  2018cites this paper
• Pancreatic cancer as a sentinel for hereditary cancer predisposition

  2018influential citation
• Association Between Inherited Germline Mutations in Cancer Predisposition Genes and Risk of Pancreatic Cancer

  2018cites this paper
• Pankreasfrühkarzinom

  2018cites this paper
• Diagnostic and prognostic impact of mucin 1–6 expression in non-small cell lung cancer

  2018cites this paper
• Synthetic Lethality: Achilles Heel in Select Patient Subpopulations

  2018cites this paper
• Nouvelle approche expérimentale en génétique constitutionnelle des maladies humaines

  2018cites this paper
• Multigene Hereditary Cancer Panels Reveal High-Risk Pancreatic Cancer Susceptibility Genes

  2018cites this paper
• Managing Patient with Mutations in PALB2, CHEK2, or ATM

  2018cites this paper
• Germline mutation prevalence in individuals with pancreatic cancer and a history of previous malignancy

  2018cites this paper
• Characteristics and Clinical Outcomes of Individuals at High Risk for Pancreatic Cancer: A Descriptive Analysis from a Comprehensive Cancer Center

  2018cites this paper
• High Prevalence of Hereditary Cancer Syndromes and Outcomes in Adults with Early-Onset Pancreatic Cancer

  2018cites this paper
• Incidence of Pathogenic Variants in Those With a Family History of Pancreatic Cancer

  2018cites this paper
• Germline Variants and Risk for Pancreatic Cancer: A Systematic Review and Emerging Concepts

  2018cites this paper